JP2019509756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509756A5 JP2019509756A5 JP2018551404A JP2018551404A JP2019509756A5 JP 2019509756 A5 JP2019509756 A5 JP 2019509756A5 JP 2018551404 A JP2018551404 A JP 2018551404A JP 2018551404 A JP2018551404 A JP 2018551404A JP 2019509756 A5 JP2019509756 A5 JP 2019509756A5
- Authority
- JP
- Japan
- Prior art keywords
- tsrna
- vector
- cancer
- trans
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 60
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 58
- 210000004027 cell Anatomy 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 102000018832 Cytochromes Human genes 0.000 claims description 8
- 108010052832 Cytochromes Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000000090 biomarker Substances 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 206010010144 Completed suicide Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- 229960004413 flucytosine Drugs 0.000 claims description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 4
- 229960002963 ganciclovir Drugs 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 238000001638 lipofection Methods 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 208000016361 genetic disease Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000010361 transduction Methods 0.000 claims description 3
- 230000026683 transduction Effects 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 2
- 241000710929 Alphavirus Species 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241001518086 Bartonella henselae Species 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 2
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000710961 Semliki Forest virus Species 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000008526 Wells syndrome Diseases 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 229940092524 bartonella henselae Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940118764 francisella tularensis Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000009429 hemophilia B Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 229940115931 listeria monocytogenes Drugs 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 201000004931 neurofibromatosis Diseases 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000004214 philadelphia chromosome Anatomy 0.000 claims description 2
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 241000187654 Nocardia Species 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- UTESHVANCFLTQV-UHFFFAOYSA-N 2,4-dinitrobenzamide Chemical group NC(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UTESHVANCFLTQV-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187681 Nocardia sp. Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007703 enzymatic ligation assisted by nucleases technique Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023011523A JP7570125B2 (ja) | 2016-04-01 | 2023-01-30 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1605586.5 | 2016-04-01 | ||
| GB201605586 | 2016-04-01 | ||
| PCT/SG2017/050183 WO2017171654A1 (en) | 2016-04-01 | 2017-03-31 | Trans-splicing rna (tsrna) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023011523A Division JP7570125B2 (ja) | 2016-04-01 | 2023-01-30 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509756A JP2019509756A (ja) | 2019-04-11 |
| JP2019509756A5 true JP2019509756A5 (enExample) | 2020-05-14 |
| JP7229467B2 JP7229467B2 (ja) | 2023-02-28 |
Family
ID=59966148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551404A Active JP7229467B2 (ja) | 2016-04-01 | 2017-03-31 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
| JP2023011523A Active JP7570125B2 (ja) | 2016-04-01 | 2023-01-30 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023011523A Active JP7570125B2 (ja) | 2016-04-01 | 2023-01-30 | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11517583B2 (enExample) |
| EP (1) | EP3436590A4 (enExample) |
| JP (2) | JP7229467B2 (enExample) |
| CN (1) | CN109642241B (enExample) |
| AU (1) | AU2017240703B2 (enExample) |
| SG (1) | SG11201808538QA (enExample) |
| WO (1) | WO2017171654A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021076656A1 (en) * | 2019-10-15 | 2021-04-22 | University Of Massachusetts | Rna editor-enhanced rna trans-splicing |
| EP4100533A1 (en) * | 2020-02-07 | 2022-12-14 | University of Rochester | Ribozyme-mediated rna assembly and expression |
| GB202102118D0 (en) | 2021-02-15 | 2021-03-31 | Cambridge Entpr Ltd | RNA Trans-Splicing molecule |
| EP4323391A4 (en) * | 2021-04-15 | 2025-04-16 | Tacit Therapeutics, Inc. | HIGH-EFFICIENCY TRANS-SPLICING FOR TARGETED RNA SEQUENCE REPLACEMENT IN HUMAN CELLS |
| GB202108855D0 (en) | 2021-06-21 | 2021-08-04 | Cambridge Entpr Ltd | Methods of eukaryotic gene expression |
| CN113584169B (zh) * | 2021-07-28 | 2024-06-18 | 南京大学 | 一种与肝癌相关的血清tsRNA标志物、探针及其应用 |
| JP2024533163A (ja) * | 2021-09-03 | 2024-09-12 | タシト・セラピューティクス・インコーポレーテッド | スプライソソーム構成要素のリクルートを介したｒｎａ編集 |
| US20250145990A1 (en) * | 2022-01-18 | 2025-05-08 | National University Of Singapore | Trans-splicing rna (tsrna) |
| KR20250011939A (ko) | 2022-05-13 | 2025-01-22 | 아시디엔 테라퓨틱스, 인크. | Abca4 트랜스-스플라이싱 분자 |
| EP4558631A4 (en) * | 2022-07-19 | 2026-07-15 | Tacit Therapeutics Inc | SYSTEMS AND METHODS TO PROMOTE TRANS-SPLICING |
| CN122206801A (zh) * | 2023-10-18 | 2026-06-12 | 泰思特治疗公司 | 反式剪接核酸分子及其使用方法 |
| CN118813791A (zh) * | 2024-09-14 | 2024-10-22 | 中国人民解放军总医院第二医学中心 | 用于诊断寒冷暴露致心肌损伤的生物标志物、试剂盒及应用 |
| EP4756023A1 (en) * | 2024-12-06 | 2026-06-10 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Self-cleavable ribozyme therapeutic nucleic acid molecules |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0883344B2 (en) * | 1995-12-15 | 2010-06-09 | VIRxSYS Corporation | Therapeutic molecules generated by trans-splicing |
| US6280978B1 (en) * | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| DE10139492B4 (de) * | 2001-08-13 | 2004-06-09 | Eul, Joachim, Dr. | Verfahren zur Reparatur einer mutierten RNA aus einer gendefekten DNA und zum gezielten Abtöten von Tumorzellen durch RNA-Transspleißen sowie Verfahren zum Nachweis von natürlich-transgespleißter zellulärer RNA |
| ATE506436T1 (de) * | 2002-04-30 | 2011-05-15 | Icon Genetics Gmbh | Auf trans-splicing basierende amplifikationsvectoren |
| WO2003104412A2 (en) * | 2002-06-05 | 2003-12-18 | Intronn, Inc. | Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling |
| AU2003285009B2 (en) * | 2002-10-23 | 2010-10-07 | Virxsys Corporation | Screening methods for identification of efficient pre-trans-splicing molecules |
| US7192709B2 (en) * | 2004-03-15 | 2007-03-20 | Digigenomics Co., Ltd. | Methods for identification, assessment, prevention, and therapy of cancer |
| KR100958293B1 (ko) * | 2008-03-27 | 2010-05-19 | 단국대학교 산학협력단 | 테오필린에 의해 표적 특이적 ｒｎａ 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 ｉ 리보자임 |
| KR20110036996A (ko) * | 2009-10-05 | 2011-04-13 | 전남대학교산학협력단 | 편평세포암 진단 마커인 ｈｏ-1 및 이의 용도 |
| WO2012056441A1 (en) * | 2010-10-28 | 2012-05-03 | Nanodoc Ltd. | Compositions and methods for specific cleavage of exogenous rna in a cell |
| JP2014525754A (ja) * | 2011-08-12 | 2014-10-02 | バイレクシス コーポレイション | アポトーシスを誘導するための組成物および方法 |
| KR101293620B1 (ko) | 2011-08-19 | 2013-08-13 | 국립암센터 | 트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도 |
| GB201219762D0 (en) * | 2012-11-02 | 2012-12-19 | Bauer Johann | A RNA trans-splicing molecule (RTM) for use in the treatment of cancer |
| KR101429696B1 (ko) * | 2012-11-21 | 2014-08-13 | 국립암센터 | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 |
| US20140283156A1 (en) * | 2013-03-14 | 2014-09-18 | Cold Spring Harbor Laboratory | Trans-splicing ribozymes and silent recombinases |
-
2017
- 2017-03-31 WO PCT/SG2017/050183 patent/WO2017171654A1/en not_active Ceased
- 2017-03-31 JP JP2018551404A patent/JP7229467B2/ja active Active
- 2017-03-31 US US16/090,226 patent/US11517583B2/en active Active
- 2017-03-31 EP EP17776008.9A patent/EP3436590A4/en active Pending
- 2017-03-31 SG SG11201808538QA patent/SG11201808538QA/en unknown
- 2017-03-31 AU AU2017240703A patent/AU2017240703B2/en active Active
- 2017-03-31 CN CN201780034177.5A patent/CN109642241B/zh active Active
-
2022
- 2022-11-10 US US17/984,846 patent/US20240075051A1/en active Pending
-
2023
- 2023-01-30 JP JP2023011523A patent/JP7570125B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023055809A5 (enExample) | ||
| Ginn et al. | Gene therapy clinical trials worldwide to 2023—an update | |
| JP7570125B2 (ja) | トランス－スプライシングＲＮＡ（ｔｓＲＮＡ） | |
| Geng et al. | Viral and non-viral vectors in gene therapy: current state and clinical perspectives | |
| Nayak et al. | Progress and prospects: immune responses to viral vectors | |
| Lu et al. | Overcoming pharmaceutical bottlenecks for nucleic acid drug development | |
| JP2021505159A (ja) | 修飾型閉端ｄｎａ（ｃｅｄｎａ）を使用する遺伝子編集 | |
| JP2024533311A (ja) | ゲノムを調節するための方法及び組成物 | |
| JP2021511047A (ja) | 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス | |
| US20200172913A1 (en) | Peptides and nanoparticles for intracellular delivery of virus | |
| US20210017518A1 (en) | Modified tracrrnas grnas, and uses thereof | |
| JP2018500391A (ja) | 対象とする細胞を選択的に除去する方法及び組成物 | |
| US20250257342A1 (en) | Peptides and nanoparticles for intracellular delivery of genome-editing molecules | |
| EP3464323A1 (en) | Peptides and nanoparticles for intracellular delivery of genome-editing molecules | |
| EP3154560A1 (en) | Methods and materials for increasing viral vector infectivity | |
| JP2021513866A5 (enExample) | ||
| JP2022525302A (ja) | フェニルアラニンヒドロキシラーゼ（ｐａｈ）治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 | |
| JP2024150579A (ja) | ゲノム配列変異を有する細胞死滅誘導用組成物及び該組成物を用いた細胞死滅誘導方法 | |
| US20250145990A1 (en) | Trans-splicing rna (tsrna) | |
| KR20250141243A (ko) | 데그론 융합 단백질 및 그의 생산 및 사용 방법 | |
| Ramirez-Phillips et al. | Therapeutic genome editing and in vivo delivery | |
| JP2025511873A (ja) | 組織特異的発現のためのプロモータースイッチ | |
| Ghanbari et al. | A preliminary step of a novel strategy in suicide gene therapy with lentiviral vector | |
| Youssef et al. | Genetic Engineering Methods in Primary T Cells | |
| CN112823209A (zh) | 使用编码高度紧凑的多输入逻辑门的核酸载体治疗疾病的方法 |